Nimenrix™, a quadrivalent meningococcal conjugate vaccine against serogroup A, C, W135 & Y, provides persistent protection to individuals aged from 6 weeks without an upper age limit. Individuals aged 1 or above only need one convenient dose 1. It also is the only quadrivalent meningococcal conjugate vaccine approved by the European Medicine Agency (EMA) & Hong Kong Department of Health for individuals aged from 6 weeks in Hong Kong.

Nimenrix™ has been registered in over 60 countries and areas worldwide. It is a booster dose to individuals previously vaccinated with a plain polysaccharide meningococcal vaccine.

Purchase Remark: Must prescribe and inject by doctors.